205 related articles for article (PubMed ID: 35501919)
21. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
22. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
23. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
Front Immunol; 2022; 13():965331. PubMed ID: 36131935
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
25. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
27. Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
Sokolenko A; Preobrazhenskaya E; Marchetti C; Piermattei A; Zagrebin F; Kuligina E; Gorodnova T; Pavone M; Ivantsov A; Bizin I; Scambia G; Berlev I; Fagotti A; Imyanitov E
Pathobiology; 2024; 91(2):108-113. PubMed ID: 37579727
[TBL] [Abstract][Full Text] [Related]
28. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
29. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
31. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
[TBL] [Abstract][Full Text] [Related]
32. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
33. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract][Full Text] [Related]
34. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
35. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
36. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
38. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
39. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy.
Octeau D; Kessous R; Klein K; Kogan L; Pelmus M; Ferenczy A; Greenwood CMT; Van Kempen LC; Salvador S; Lau S; Tonin PN; Yasmeen A; Gotlieb WH
Mol Cancer Res; 2019 Dec; 17(12):2422-2431. PubMed ID: 31530633
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
